Table 5.
Statistical difference ( P values) between the performance of PET/CT and cePET/CT for each analyzed tumor type, site of disease, and clinical question
| P value | |
|---|---|
|
Tumor type |
|
| Lung cancer |
0.12 |
| Head and neck cancer |
0.02 |
| Gastrointestinal cancera |
0.0002 |
| Breast cancer |
0.09 |
| Lymphoma |
0.24 |
| Melanoma |
0.16 |
| Multiple melanoma |
0.08 |
| Otherb |
0.33 |
|
Site of disease |
|
| Neck |
0.096 |
| Thorax |
0.36 |
| Abdomen |
0.009 |
| Skeleton-bone marrow |
0.33 |
| Lymph nodes |
0.44 |
|
Clinical question |
|
| Diagnosis |
0.39 |
| Staging |
0.09 |
| Restagingc |
0.003 |
| Response to chemotherapy |
0.13 |
| Response to radiotherapy |
0.1 |
| Post-surgery evaluation |
0.54 |
| Surveillance | 0.51 |
aIncluding esophageal, gastric, and colorectal cancer.
bGynecologic malignancy n = 8 , testicular cancer n = 2, sarcoma n = 3, low-differentiated neuroendocrine carcinoma n = 4, thymoma n = 1.
cSuspected relapse or patients with potentially resectable metastatic disease.
PET, positron emission tomography; CT, computed tomography; cePET/CT, contrast-enhanced PET/ CT.